Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lowering the prophylactic platelet transfusion threshold: a prospective analysis.

J B Lawrence1, R A Yomtovian, T Hammons

  • 1Institute of Pathology; Reserve University and University Hospitals of Cleveland, OH 44106, USA.

Leukemia & Lymphoma
|May 9, 2001
PubMed
Summary

Lowering the prophylactic platelet transfusion threshold from 20 to 10 x 10(9)/L in hematology-oncology patients significantly reduced platelet use without increasing hemorrhage. This 10 x 10(9)/L threshold is safe and effective.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given.

Leukemia·2025
Same author

Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

Bone marrow transplantation·2024
Same author

Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

Bone marrow transplantation·2024
Same author

A modest proposal to the transplant publik to prevent harm to people with acute myeloid leukaemia in 1st complete remission cured by chemotherapy.

Leukemia·2024
Same author

Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes

Current oncology (Toronto, Ont.)·2020
Same author

Differential expression of interferon-induced genes and other tissue-based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skin.

Clinical and experimental dermatology·2018

Area of Science:

  • Hematology
  • Oncology
  • Transfusion Medicine

Background:

  • The standard prophylactic platelet transfusion threshold of 20 x 10(9)/L is debated.
  • Limited prospective studies exist on lower trigger values for platelet transfusions.

Purpose of the Study:

  • To evaluate the safety and efficacy of a lower prophylactic platelet transfusion threshold (10 x 10(9)/L) compared to the standard threshold (20 x 10(9)/L).

Main Methods:

  • A prospective, observational study was conducted over one year in hospitalized adult hematology-oncology patients.
  • The prophylactic platelet transfusion threshold was set at 20 x 10(9)/L for the first six months (baseline) and 10 x 10(9)/L for the second six months (study period).
  • Patients were monitored daily for hemorrhage and platelet transfusion use.

Related Experiment Videos

Main Results:

  • Mean platelet transfusion use per patient per day was significantly lower with the 10 x 10(9)/L threshold (4.47) compared to the 20 x 10(9)/L threshold (6.48).
  • Both prophylactic and therapeutic platelet transfusions decreased in the study period.
  • Hemorrhage rates (major and minor) were slightly reduced in the study period, indicating no increase in bleeding with the lower threshold.

Conclusions:

  • A prophylactic platelet transfusion threshold of 10 x 10(9)/L is safe and effective in hospitalized adult hematology-oncology patients.
  • Lowering the platelet transfusion threshold can significantly reduce transfusion utilization.
  • This strategy supports more conservative transfusion practices in oncology care.